Lupin is currently trading at Rs 660.00, up by 15.10 points or 2.34% from its previous closing of Rs 644.90 on the BSE.
The scrip opened at Rs 647.70 and has touched a new high of Rs 661.60 and low of Rs 638.25 respectively. So far 46206 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 649.00 on 11-Apr-2013 and a 52 week low of Rs 507.00 on 18-Jun-2012.
Last one week high and low of the scrip stood at Rs 649.00 and Rs 606.20 respectively. The current market cap of the company is Rs 29465.34 crore.
The promoters holding in the company stood at 46.85% while Institutions and Non-Institutions held 43.40% and 9.75% respectively.
Foreign institutional investors (FIIs) have hiked their shareholding in pharma major, Lupin, to historic highs of 28.8% in March 2013 quarter from 27.76% at the end of December 2012 quarter. FIIs bought 4.66 million shares worth of Rs 279 crore in January-March quarter.
Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1941.00 |
| Dr. Reddys Labs. | 1152.60 |
| Cipla | 1410.90 |
| Lupin | 2369.45 |
| Zydus Lifesciences | 1108.90 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: